BioSpace News Archive

Eli Lilly and Company announced its financial results for the first quarter of 2024.

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the submission of a New Drug Application to the U.S. Food and Drug Administration for approval of ET-400, Eton’s proprietary patented formulation of hydrocortisone oral solution.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that it has enrolled the 200th patient in its ongoing SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions.

I-Mab, a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission on April 30, 2024.

Harmony Biosciences, announced the acquisition of Epygenix Therapeutics, Inc., accelerating its growth strategy by adding a rare epilepsy franchise to its expanding late-stage pipeline of innovative CNS assets.

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer.

Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, announced that Eversense® has been granted an integrated CGM designation by the US Food and Drug Administration.

Emmetrope Ophthalmics LLC, a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, announced final dose administration for the last patient in its U.S. randomized, double-masked, multi-center trial assessing the safety and efficacy of EO2002 for the treatment of corneal edema.

Enanta Pharmaceuticals, Inc. announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals’ Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta’s new Chief Legal Officer.

Repare Therapeutics Inc., a leading clinical-stage precision oncology company, and Debiopharm, a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC clinical trial investigating lunresertib in combination with Debio 0123.